Chapter 2
What Is Quality Health Care for Cancer
Survivors?
Jennifer Malin, Emma-Jane Sayers, and Michael Jefford
Introduction
Defining Cancer Survivorship
The term “cancer survivor” has been used to identify different populations affected
by cancer [1, 2]. The National Coalition for Cancer Survivorship (NCCS) suggests
“an individual is considered a cancer survivor from the time of diagnosis, through
the balance of his or her life [3].” This definition, which has been adopted by the
National Cancer Institute Office of Cancer Survivorship, covers family members,
friends, and caregivers, who are also affected by the survivorship experience. It also
acknowledges that cancer affects people for the rest of their lives. Traditionally, to
“survive cancer” has meant to be cured of or to appear to be free from cancer.
Measures such as 5-year disease-free (or overall) survival [2] have been deployed
to mark out the survivor period. More recently, the meaning of “cancer survivorship” has been broadened to signify the period following potentially curative treatments; notably, the influential Institute of Medicine (IOM) report, From Cancer
Patient to Cancer Survivor: Lost in Transition, focuses on this period [4]. This definition does not explicitly include family and caregivers, so we must remember that
cancer also affects those close to the person with cancer. We must also remember
that the survivor experience is a continuum, which includes diagnosis and treatment, and may also include recurrence, living with advanced cancer, and death.
J. Malin (*)
Jonsson Comprehensive Cancer Center, University of California,
Los Angeles and Greater Los Angeles Veterans Administration, Los Angeles, CA, USA
e-mail: drjmalin@gmail.com
M. Feuerstein and P.A. Ganz (eds.), Health Services for Cancer Survivors,
DOI 10.1007/978-1-4419-1348-7_2, © Springer Science+Business Media, LLC 2011
27
28
J. Malin et al.
Importance of Continued Care for Cancer Survivors
There is increasing awareness of challenges that survivors may experience following
completion of primary treatment. They may experience physical, psychological,
and social consequences of cancer and its treatments [5–11]. Survivors may feel
abandoned by their cancer treatment team and experience fear of cancer recurrence,
uncertainty about the future, difficulties returning to work and social situations,
financial problems, and issues managing long-term and late effects of treatment
[5–11]. The risk of second or recurrent cancers is increased for survivors, who also
face illnesses such as heart disease and arthritis that affect older populations [12].
Care beyond the period of acute treatment needs to include appropriate management of such problems to improve survivor outcomes [13, 14]. In its recommendations regarding the transition from cancer patient to cancer survivor, the IOM
recommended that “health care providers, patient advocates, and other stakeholders
should work to raise awareness of the needs of cancer survivors, establish cancer
survivorship as a distinct phase of cancer care, and act to ensure the delivery of
appropriate survivorship care” [4]. This chapter provides a discussion of just what
“the delivery of appropriate survivorship care” is.
Current Survivorship Care
Care of cancer survivors appears to be suboptimal [4]. Follow-up care between the
oncology specialist (surgical, medical, and radiation oncologists) and primary care
provider may be poorly coordinated, meaning that the survivor risks either duplication of effort or gaps in care. A too-narrow medical focus on surveillance for recurrence, metastases, or new primary cancers may overlook late physical and
psychosocial effects, including the impact of cancer on the survivor’s life. Advice
and strategies that promote healthy living and psychosocial well-being are rarely
discussed; when they are, this is usually ad hoc, inconsistent, and without a sound
evidence base [4, 15, 16].
Patients often lack necessary information and continuing support [7]. In Hewitt’s
research on posttreatment cancer care, most survivors reported satisfaction with current medical care, but not with how their psychosocial needs were met. At the end of
treatment they felt overwhelmed, but were rarely given written information [17].
I think it’s just one of those things that during the treatment period you’ve got a, like, a
schedule that you’re running to, and everyone runs to that. There’s a plan.
And everyone knows, “Right, well, I can help this way by I’ll drive you to that chemo session. I’ll do this on it.” And everyone can say “Now, alright, you cook the meals this week;
I’ll do it that week.” All that wonderful support that’s around you from your family and
friends, you come out of treatment, when you get the sort of “OK, it’s all over,” no one
knew quite what to do. And now, is it all just going to be magically better? And I was all
prepared for the amount of time it was going to take for me to feel better after the chemo
and that, because it took forever before I felt human again, and no one quite knew what to
ask me to do at work, how much more to put back on me, all that sort of thing [6].
2
What Is Quality Health Care for Cancer Survivors?
29
After my good news, a year after treatment, I spat up blood, and I went “Oh dear, it’s back.”
I was taken in; they looked down and couldn’t find anything. Patted me on the head and
sent me home. For the next five years I was waiting to be spitting up blood again, until I
finally did. So I came back here, and they said, “Don’t worry about it. It happens.” Now, if
somebody had told me that five years before, I wouldn’t have been worried about it coming
back so much [6].
In a large Internet-based study conducted by the Lance Armstrong Foundation,
33% of survivors reported there were few or no resources available to deal with
their emotional needs; 70% felt that their physician was unable to assist with identified nonmedical issues [18].
Importantly, optimal survivorship care does not begin as treatment ends. Optimal
posttreatment outcomes are strongly influenced by experiences and interventions
that take place much earlier, including at diagnosis and during treatment. Identifying
and addressing supportive care needs early may result in improved outcomes
[15, 16, 19]. For example, meeting informational needs and providing necessary
practical and emotional support is likely to reduce distress following treatment
completion and into the survivorship phase. Similarly, medical interventions during
the treatment phase may prevent later consequences. For example, with appropriate
intervention, it may be possible to reduce the risk of premature menopause, infertility, sexual dysfunction, and cognitive problems.
Over the past 15 years, there has been increasing pressure for better services for
survivors:
• In 1996, the National Coalition for Cancer Survivorship established 12 principles for delivering quality cancer care [20].
• There has been extensive investigation into the types of changes needed to
improve the quality of care, including the 2001 IOM report Crossing the Quality
Chasm: A New Health System for the 21st Century [21].
• In 2005 the IOM released From Cancer Patient to Cancer Survivor: Lost in
Transition, which comprehensively examines the need for improved care for
survivors [4].
A Framework for Considering Quality Survivorship Care
The IOM Committee on Health Care Quality in America has defined essential features to guide the redesign of health-care processes [21]. These are shown in
Table 2.1.
These general considerations provide a valuable framework for considering
ideal care for cancer patients and survivors. Importantly, the above points do not
impose a restricted consideration of patient needs. As noted, survivors may encounter a broad range of consequences as a result of cancer and its treatments. Some
might clearly be considered within the scope of medical care (treatment of side
effects, risk of late effects) and some within the broader scope of supportive care
(dealing with fear of recurrence, adjustment issues); however, other issues, for
30
J. Malin et al.
Table 2.1 Essential features to guide the redesign of health-care processes [21] (Reprinted with
permission from the National Academies Press, Copyright [2001], National Academy of Sciences)
• Carebasedoncontinuoushealingrelationships.Thesystemshouldberesponsiveand
accessible.
• Customizationbasedonpatientneedsandvalues.Thesystemshouldhavethecapabilityto
respond to individual patient choices and preferences.
• Thepatientasthesourceofcontrol.Patientsshouldbegiventhenecessaryinformationand
the opportunity to exercise the degree of control they choose over decisions that affect them.
• Sharedknowledgeandthefreeflowofinformation.
• Evidence-baseddecision-making.
• Safetyasasystemproperty.
• Theneedfortransparency.
• Anticipationofneeds.Thesystemshouldnotjustreacttoevents.
• Continuousdecreaseinwaste.
• Cooperationamongclinicians.
example, returning to school or work or coping with financial consequences, may
not be considered the focus of posttreatment care. Perspectives of the survivor,
health-care provider, and payer may indeed be quite different regarding what constitutes quality survivorship care. It will be important to continue to debate the
scope of “quality health care for cancer survivors.”
Considering the range of potential issues affecting survivors and the need for a
broad focus, it is worthwhile to highlight the World Health Organization definition
of health, that being “a state of complete physical, mental and social well-being and
not merely the absence of disease or infirmity [22].” The emphasis on well-being
accords with a notion of cancer as a chronic disease and the need for rehabilitation
following active cancer treatments.
In addition to advocating for planned and coordinated care to manage the medical and psychosocial difficulties experienced by cancer survivors after completing
treatment, the IOM report From Cancer Patient to Cancer Survivor: Lost in
Transition attempted to further describe and “operationalize” the content of what
survivorship care should involve. Four essential components of survivorship care
were identified and are presented in Table 2.2 [4].
While these four components may have broad applicability, it should be remembered that every survivor will have a unique experience. Even patients with the
same type of cancer may receive quite different treatments, be affected in very different ways, encounter individual difficulties, and be at risk of different consequences. This underscores the need to tailor follow-up to each individual survivor.
Prevention of Recurrent and New Cancers, and of Other Late Effects
Although survivors remain at a heightened risk of developing new cancers, this
risk may be reduced through health promotion strategies [14]. There is increasing
evidence to support the use of adjuvant medical treatments to reduce the risk of
cancer recurrence. In addition, the period after treatment can be seen as a
2
What Is Quality Health Care for Cancer Survivors?
31
Table 2.2 Four essential components of survivorship care
1. Prevention of recurrent and new cancers, and of other late effects
2. Surveillance for cancer spread, recurrence, or second cancers; assessment of medical and
psychosocial late effects
3. Intervention for consequences of cancer and its treatment
4. Coordination between specialists and primary care providers to ensure that all of the
survivor’s health needs are met
“teachable moment,” where changes to health and lifestyle may be more readily
adopted in an attempt to prevent disease and ill health [4]. Improved diet, maintaining a healthy weight, ceasing smoking, and increasing physical activity may
prevent secondary and recurrent cancers, and may reduce many of the physical
and psychosocial consequences of cancer treatment [23, 24]. Information on recommended health and lifestyle strategies should be provided to all cancer survivors [4, 24]. Indeed, the second recommendation of the IOM report (and relevant
to each of the four essential components of survivorship care) concerns provision
of information: “patients completing primary treatment should be provided with a
comprehensive care summary and follow-up plan that is clearly and effectively
explained. This ‘survivorship care plan’ should be written by the principal
provider(s) who coordinated oncology treatment. It is recommended that this service/procedure be reimbursed by third-party payors of health care [4].” It is possible that this coordinated effort would provide for a more systematic and even
preventive service, reducing the need for mismanaged care.
Surveillance for Cancer Spread, Recurrence, or Second Cancers;
Assessment of Medical and Psychosocial Late Effects
Ongoing surveillance is an essential component of follow-up care to ensure that
new or recurrent cancers are detected at a time when treatment may be most effective [25]. Guidelines are not available for all cancer types and vary considerably in
terms of their comprehensiveness. Many emphasize detection of cancer recurrence,
but place little emphasis on the prevention, detection, and amelioration of the consequences of cancer treatments. Many of these guidelines provide inconsistent
recommendations about the frequency, duration, and type of follow-up that is
required for different survivor groups [25]. The third recommendation from the
IOM report was that “Health care providers should use systematically developed
evidence-based clinical practice guidelines, assessment tools, and screening instruments to help identify and manage late effects of cancer and its treatment. Existing
guidelines should be refined and new evidence-based guidelines should be developed through public- and private-sector efforts [4].”
Surveillance is an ideal opportunity to monitor treatment efficacy and any ongoing physical or psychosocial consequences. It is also a time to provide continuing
information and support. Surveillance may also help survivors to feel less anxious
32
J. Malin et al.
about the possibility of cancer returning and more confident about what will happen
to them in the future. Surveillance should be tailored, with individuals at high risk
of treatment sequelae requiring a higher degree of surveillance [25]. Surveillance
also provides an added opportunity to screen for general health issues, as many
patients neglect other areas of health due to a heavy focus on cancer and recurrence
[26]. Furthermore, it has been suggested that a full review of psychosocial and
adjustment issues be incorporated into an optimal model of survivorship care [12].
Intervention for Consequences of Cancer and Its Treatment
Cancer survivors may require further assistance managing the physical and psychosocial effects of cancer diagnosis and treatment. Patients may have persisting, even
long-term effects and be at risk of developing problems at a later time – late effects.
Physical issues such as fatigue, pain, urinary and bowel issues, and hot flashes may
be successfully managed with medical interventions or self-care strategies [6, 27].
A growing number of psychosocial interventions may improve symptom management and psychological issues as they arise and should be discussed as part of a
tailored survivor consultation [28].
Coordination Among Specialists and Primary Care Providers
Follow-up care is often provided by a group of oncology specialists and primary
care providers. This system has a number of strengths, if used effectively. Cancer
screening services are received more reliably when specialists are involved; however, preventive services for other medical illnesses tend to be neglected [12]. This
may be greatly improved when a primary care provider is also involved [12].
Coordinated care between oncologists and primary care providers is essential to
ensure that all health needs are met [4, 29]. Regular, effective communication strategies are crucial to the success of such an arrangement. Care plans may assist. Clear
delineation of roles is essential. Comprehensive care means that each of the above
principles (detection, surveillance, and intervention) should be undertaken, but it is
less clear how to optimally allocate these responsibilities in a shared care model.
Elsewhere we have suggested other elements of ideal survivorship care [30].
High-quality care would:
•
•
•
•
•
Be comprehensive and accessible
Include specialized services
Be patient-centered
Be tailored to meet individual needs
Empower survivors to take a role in their own health management to the extent
that they wished
• Be multidisciplinary and collaborative and include oncologists; primary care
providers; nurses; rehabilitation specialists such as physiatrists, physical therapists, social workers and psychologists; and survivors and their families
2
What Is Quality Health Care for Cancer Survivors?
33
• Recognize the transition from acute care to the community and be designed to
facilitate this transition
• Use effective communication strategies to promote planned and coordinated
follow-up
• Be holistic and address psychosocial as well as physical needs
• Encompass preventive as well as reactive health management
• Be evidence-based and supported by appropriate guidelines, policies, and research,
to ensure that care is outcomes-focused, cost-effective, and sustainable
Defining and Measuring Quality Survivorship Care
The ultimate objective of good quality cancer care is to achieve desired outcomes
for survivors. This includes not only surviving the cancer but also living well.
Functional status, quality of life, and the personal cancer care experience emerge as
critical and perhaps overlooked outcomes [31, 32]. Thus, important outcomes for
cancer survivors include not only overall and disease-free survival but also functional status and quality of life, as well as their experience of care (satisfaction).
The IOM has defined quality as “the degree to which health services for individuals and populations increase the likelihood of desired health outcomes and are
consistent with current professional knowledge [33].” Of note, this definition refers
to health services and health outcomes. Health systems overall tend to be oriented
around the acute treatment of ill people, with lesser emphasis on prevention and
rehabilitation. Cancer is a leading cause of death. Thus, research and clinical services have developed with the primary focus being effective treatment with the goal
of cure. Quality frameworks have emphasized the treatment phase of the cancer
journey and focused on safe, effective, well-coordinated medical care. Only quite
recently has there been recognition of the posttreatment phase. Survivors may be
affected by cancer and its treatments for many decades. As noted previously, survivors’ well-being may be strongly influenced by a broad set of consequences, including impact of the illness on work, education, finances, and relationships. Therefore,
quality metrics may need to be expanded to recognize the breadth and duration of
the survivorship experience. Clarifying definitions is important, as this may strongly
affect the orientation of care and services. The fourth recommendation from the
IOM report is that “quality of survivorship care measures should be developed
through public/private partnerships and quality assurance programs implemented
by health systems to monitor and improve the care that all survivors receive [4].”
Moving beyond survival, functional status, quality of life, and the personal cancer care experience emerge as critical and perhaps overlooked outcomes [31, 32].
Cancer survivors have more functional limitations due to their health than age-,
gender-, and educational-attainment-matched controls, with 18% unable to work
due to health problems (vs 10% for controls), 27% limited in the amount or kind of
work that they can do because of health problems (vs 18%), 5% needing help in
activities of daily living (vs 3%), and 11% needing help in independent activities of
daily living (vs 7%) [34]. Survivors may have other long-term functional limitations.
34
J. Malin et al.
A high proportion of cancer survivors have limitations in lower-body function, with
56% reporting difficulty in performing at least one of the following activities
compared with only 27% of controls: walking one-quarter of a mile; walking up
and down ten steps; standing for 2 h; stooping, crouching, or kneeling; and lifting
10 lb [35]. There are opportunities to provide the type of care needed to mitigate
the impact of these functional limitations to enhance overall health.
Research is urgently needed to develop evidence-based approaches to improve
outcomes for cancer survivors. In addition, however, we must determine what processes and structures of care will produce the highest quality outcomes given current scientific knowledge.
What Is Known About the Quality of Survivorship Care?
The ultimate objective of good quality cancer care is to achieve desired outcomes for
survivors. This includes not only surviving the cancer but also living well. Thus,
important outcomes for cancer survivors include not only overall and disease-free
survival, but also functional status and quality of life, as well as their experience of
care (satisfaction). Both structure and process of care, along with individual patient
characteristics, contribute to outcomes (Fig. 2.1). The only way to improve the quality
of outcomes is to improve the quality of the process and structure of care. Process is
the set of activities that go on between patients and practitioners and includes both the
technical and interpersonal quality of care. The structural dimension of health-care
quality includes resources needed to provide medical care, such as the availability of
imaging services or the professional education and competence of the providers.
Quality Indicators for the Processes of Survivorship Care
Quality of care can be measured across three dimensions: outcomes, process, and
structure of care [36]. Measures of the process of care are referred to as “quality
indicators.” Quality indicators take the form of an “if-then” statement, which is then
represented as a ratio where the “if” is the denominator and the “then” is the
numerator:
Quality indicator =
# patients who received the specified intervention
# patients for whom the intervention is indicated
- # patients reasonable to exempt from intervention
The numerator describes the care that should be provided. The denominator
identifies the group of patients to whom the care should be provided. For example,
when specifying a quality indicator for tamoxifen for breast cancer, it is necessary
to determine which patients would be eligible, and in addition to identifying the
cohort for whom tamoxifen is indicated, it may be desirable to exclude patients who
2
What Is Quality Health Care for Cancer Survivors?
Process
Rehabilitation and reconstruction
Treatment to prevent cancer recurrence
Surveillance for recurrence
Screening for second malignancies
Assessment of symptoms and late effects of therapy
Assessment and management of
psychosocial distress
Patient-centered care
35
Outcomes
Disease-free survival
Overall survival
Functional status
Quality of Life
Satisfaction
Cost
Structure
Coverage Policies
Coverage for mental health and psychosocial care
Coverage for reconstruction and rehabiliation
Availability of Services
Imaging technology
Genetic testing
Organization
Integration of health care system
Specialized models of care i.e. Patient Centered
Medical Home
Specialized survivorship clinics
Training and Competence of Providers
Fig. 2.1 Structure and processes of care that lead to desired outcomes for cancer survivors
refused. If a patient newly diagnosed with invasive breast cancer meets all of the
criteria – is premenauposal, has estrogen receptor–positive or progesterone receptor–
positive breast cancer, tumor size greater than 1 cm or involved axillary lymph
nodes, and did not refuse tamoxifen – THEN the patient should receive tamoxifen.
To operationalize this measure, the THEN statement becomes the numerator and all
of the criteria in the IF statement need to be specified in the denominator.
Quality indicator =
# eligible patients who received tamoxifen
# premenopausal women with ER or PR positive breast
cancer > 1 cm or involved axillary lymph nodes
- # patients who refused tamoxifen
Since the IOM called attention to the quality of cancer care in its 1999 report
“Ensuring the Quality of Cancer Care [37],” a number of quality indicator sets have
been developed to evaluate the quality of cancer care [38–43]. However, few of
these quality indicators address posttreatment survivorship care and most focus on
follow-up of people with a history of breast, colorectal, or prostate cancer, or melanoma. Of the four essential components of survivorship care described by the IOM
(and discussed above), almost all of the indicators are focused on the second element (surveillance for cancer spread, recurrence, or second cancers; assessment of
medical and psychosocial late effects) and most focus on detection of recurrence.
Of the quality indicators that address aspects of survivorship care (see Table 2.3),
nine address surveillance (essential component 2) and the domains of prevention
(essential component 1), consequences of cancer treatment (essential component 3), and
36
J. Malin et al.
Table 2.3 Cancer survivorship quality indicators
Cancer
type
Quality indicator
All
Chemotherapy treatment summary completed;
provided to patient; and communicated or
provided to other practitioner(s) within 3 months
of chemotherapy end.
Smoking cessation counseling recommended to
cigarette smokers by second office visit.
Breast
cancer
Colorectal
cancer
Prostate
cancer
If a patient with stage I–III breast cancer who initiates
treatment with tamoxifen does not meet the
following criteria for discontinuing tamoxifen: there
is evidence of disease progression, then the patient
should receive 5 years of tamoxifen 20 mg/day.
If a patient with stage I–III breast cancer undergoes
mastectomy, then prior to undergoing mastectomy
the patient should be informed about the option of
breast reconstruction after mastectomy.
If a patient has been diagnosed with stage I–III breast
cancer and has not had bilateral mastectomies, then
the patient should have had a mammogram in the
last 12 months.
Women with a history of breast cancer should have
yearly mammography.
Women diagnosed with breast cancer in the past
5 years should have a clinical breast exam in the
past 6 months.
Women diagnosed with breast cancer more than 5 years
ago should have a clinical breast exam in the past year.
If the patient has resection of a stage II or stage III
colon rectal cancer, then the patient should be
counseled about the need to have first degree
relatives undergo colorectal cancer screening.
Patients with stage I–III colorectal cancer, then he/
she should receive colonoscopy or double contrast
barium enema within 1 year of curative surgery if it
did not occur within 12 months preoperatively.
Patients with stage I–III colorectal cancer should
receive colonoscopy or double contrast barium
enema within 3 years of curative surgery and every
5 years thereafter.
Documentation/evidence of communication with
patient’s primary care physician or provision of
continuing care.
At least two visits for follow-up by treating physician
during the first posttreatment year.
Indicator
set
QOPI
Level of
evidence
III
QOPI
II
NICCQ
I
NICCQ
III
NICCQ
I
QATOOL
(RAND)
QATOOL
(RAND)
I
III
QATOOL
(RAND)
III
NICCQ
II
QATOOL
(RAND)
II
QATOOL
(RAND)
I
RAND
prostate
III
RAND
prostate
III
III
Patients with a personal history of cutaneous melanoma QATOOL
(RAND)
should receive a referral to a dermatologist for
surveillance screening.
QOPI Quality Oncology Practice Initiative, NICCQ National Initiative on Cancer Care Quality,
QATOOL Quality Assessment Tool, RAND the RAND Corporation (Research And Development)
Melanoma
2
What Is Quality Health Care for Cancer Survivors?
37
coordination between specialists and primary care providers (essential component 4)
each have just one quality indicator. Additionally, only three are based on Level I
evidence (adjuvant therapy with tamoxifen and screening for second cancers with
mammography and colonoscopy).
Are Patients Receiving the Essential Components of Quality
Survivorship Care?
Given the paucity of validated quality indicators, our knowledge of the quality of
the process of care for cancer survivors is limited. Nevertheless, in recent years, a
number of studies provide valuable insights on the quality of survivorship care.
Poor quality of care can result from too little care (underuse), too much care
(overuse), or the wrong care (misuse). Most quality measurement has focused on
underuse or misuse. Overuse of an intervention is an important indicator of poor
quality when the potential for harm exceeds the potential benefit to patients.
Overuse that does not have an adverse risk–benefit ratio may not be an indicator of
poor quality care for the individual patient but may be undesirable because it results
in inefficient resource allocation. Given the paucity of evidence-based quality indicators for survivorship care, our knowledge of the quality of survivorship care is
somewhat limited. Nevertheless, the available data suggest that we are falling short
on delivering the essential components of survivorship care proposed by the IOM.
Prevention of Recurrent and New Cancers, and of Other
Late Effects
Unfortunately, few strategies currently exist for preventing recurrent or new primary cancers (beyond adjuvant therapy) and little is known about preventing late
effects of treatment, although lifestyle factors, such as ceasing cigarette smoking,
maintaining a healthy weight range, and regular exercise, may assist [23].
Nevertheless, the available data suggest that prevention efforts are lacking for those
cancers where the evidence does demonstrate a benefit. Smoking cessation has
been shown specifically to improve the outcomes of patients with lung cancer and
head and neck cancer [44]. Additionally, smokers with a non-tobacco-related
malignancy may be more receptive to counseling as their experience with cancer
providing a “teachable moment [45].” Of course, stopping smoking has many other
health benefits. In 2006 American Society of Clinical Oncology (ASCO) began
integrating smoking-related measures into the ASCO Quality Oncology Practice
Initiative (QOPI), a quality improvement program that enables oncology practices
to assess their performance relative to their peers on a menu of quality measures.
Among QOPI practices, smoking cessation counseling is offered to smokers only
approximately 25% of the time [46]. Given that these are a self-selected group of
38
J. Malin et al.
practices interested in quality improvement, this rate likely overestimates the rate
of patients counseled about smoking prevention overall.
Most women with hormone receptor–positive breast cancer are prescribed
hormonal therapy with tamoxifen or an aromatase inhibitor at the completion of the
initial treatment not only to decrease their risk of distant recurrence but also to
prevent local recurrence and second breast cancers. Although the rates of appropriate prescribing of adjuvant hormonal therapy are very high, the available data suggest that the quality of care to ensure that patients continue to receive this important
therapy needs to be improved. In the NICCQ study, while 92% of women with
hormone receptor breast cancers larger than 1 cm or positive lymph nodes received
tamoxifen, only 74% of those who initiated therapy were still taking the medication
when surveyed 4 years after diagnosis [47]. Other studies have reported even higher
rates of discontinuation of tamoxifen ranging from 31% to 49% in women over 65
[48, 49]. Factors predicting non-adherence include older age and greater comorbidity but also having side effects from the medication [49], not being informed about
side effects in advance of starting the medication, and having less support than
needed [50], suggesting that adherence may improve with greater attention to the
quality of survivorship care.
Surveillance for Cancer Spread, Recurrence, or Second Cancers;
Assessment of Medical and Psychosocial Late Effects
There is strong evidence supporting the benefit of surveillance for new primaries for
a number of cancers, including breast cancer, colorectal cancer, and consensus
regarding the practice for others such as melanoma. While the data concerning the
benefits of surveillance for local recurrence are less certain, the same modalities
used to screen for a new primary would generally identify a local recurrence (e.g.,
mammogram and breast exam). Rates of adherence to mammography screening
quality indicators are generally very high. In NICCQ, 94% of breast cancer survivors reported having received a mammogram in the prior year [47]. Rates of mammography are lower in older breast cancer survivors but still far exceed the
mammography screening rates of women without a cancer history or who have other
comorbid conditions (73% vs 59% vs 38%, respectively, for women enrolled in
Medicare) [51]. Similarly, among colorectal cancer survivors, most appear to receive
recommended colonoscopy screening with overall 74% having at least one colonoscopy within 3 years of diagnosis, with the proportion appropriately declining with
age (83% of survivors 66–69 vs 47% of survivors 85 and older) and comorbidity
(75% with no comorbid conditions and 69% with three or more comorbid conditions) [52]. Since patients with melanoma are at high risk for a second skin cancer,
routine physical examination of the skin is recommended. In one study, more than
90% of Medicare patients diagnosed with melanoma in the US Surveillance,
Epidemiology, and End Results (SEER) registry had a visit with a clinician for a skin
examination within 2 years of their diagnosis [53]. Thus, while there may still be
room for improvement, especially to address areas of health disparities, overall, at
2
What Is Quality Health Care for Cancer Survivors?
39
least for common cancers where consensus exists on appropriate surveillance, the
quality of care for detection of second cancers appears quite good.
Unfortunately, for only a handful of cancers does early identification of distant
recurrence appear to result in improved outcomes. Randomized trials have found
that for a number of cancers, including breast cancer and ovarian cancer, intensive
monitoring for disease recurrence not only does not prolong survival but may
worsen quality of life by adding to the number of months of palliative chemotherapy received [54, 55]. Because of this, clinical guidelines recommend against routine surveillance for cancer recurrence using tumor markers or imaging, except in
those situations where early treatment has been shown to improve patient outcomes, such as resection of liver metastases in colorectal cancer or high-dose chemotherapy for lymphoma.
Given that until recently, the primary focus of care for cancer survivors has been
on identifying relapses, it is perhaps not surprising that there appears to be extensive
overuse of testing to detect cancer recurrences. Use of medical imaging in general
has been increasing dramatically in recent years, with PET scanning becoming the
most widely used imaging for patients with cancer in the USA [56–58]. Much of this
increase reflects the overuse of these tests to detect cancer recurrences. In the US
National Oncology PET Registry, 65% of PET scans were obtained for detection of
recurrences despite the fact that guidelines do not recommend imaging surveillance
for any of the nine malignancies that are included [58]. A recent study estimated that
while cancer patients represented only 1% of the patients receiving imaging studies
in Germany in 2000–2005, they received more than 10% of the effective dose of
radiation delivered during that time [59]. The unfortunate irony is that this inappropriate surveillance for a cancer recurrence may place cancer survivors at increased
risk for second primaries and other malignancies [60, 61].
Assessment of medical and psychosocial late effects has not been systematically
studied, though appears suboptimal. As an illustration, Beaker and Luker studied
the nature and content of hospital follow-up for women with early breast cancer
[62]. Consultations were generally quite short (mean duration of 6 min) and
focused on the detection of cancer recurrence. Unsurprisingly, few opportunities
were available to meet supportive care needs. However, patients gained reassurance
from these visits, as they were generally very optimistic.
Intervention for Consequences of Cancer and Its Treatment
Cancer and its treatments are associated with numerous physical and emotional
consequences. While effective approaches to mitigate the effects of cancer treatment
are sorely lacking, interventions do exist for a growing number. The consequences
of often disfiguring cancer surgeries have long been recognized and several quality
indicators speak to the need to address these issues. Although only 20–40% of
women undergo breast reconstruction following mastectomy [63], over 80% report
discussing reconstruction with their physicians [63, 64]. The NICCQ study included
a quality indicator for breast reconstruction for women who have a mastectomy
which recommends that prior to undergoing mastectomy the patient should be
40
J. Malin et al.
informed about the option of breast reconstruction after mastectomy. In the NICCQ
cohort there was widespread variation in adherence to this quality indicator with just
over half of the patients receiving the specified care, but across cities this ranged
from 39% to 65% [47]. Similarly, for patients with colorectal cancer who receive an
ostomy during their primary surgery, reversal of the ostomy is critical for quality of
life during survivorship when feasible and while data are limited, they suggest that
this is often not performed after the patient completes their initial treatment. In the
NICCQ study, 40% of patients with stage II rectal cancer and just 3% of patients
with stage III rectal cancer had their ostomy reversed, although this included both
patients who had abdominoperineal resections as well as low anterior resections, so
some may not have been candidates for ostomy closure [65]. In contrast, a recent
study of an intervention to increase the timeliness of ostomy closure by “setting a
date” at the time of discharge from their primary surgery reported that 72% of
patients undergoing low anterior resections had their ostomies closed [66]. These
data suggest that there are widespread problems with the quality of survivorship care
in the area of interventions to improve the consequences of cancer and its treatment,
even when a well-accepted procedure is available and supported by guidelines.
The prevalence and time course of psychological distress in cancer survivors is
not well described. Depression in survivors has been estimated to range from 10%
to 58%, anxiety disorders reverse from 23% to 65%, and posttraumatic stress disorder from 0% to 32% [31]. A recent study found that while most patients did not
report unmet supportive care needs following completion of their cancer treatment,
30% reported at least one unmet psychological need and for most the need persisted
6 months later [67]. While little is known about how or when to screen for distress
[68] nor how best to intervene – currently available guidelines for the psychosocial
care of patients with cancer do not address the posttreatment period [69] – this
clearly is an area where attention to improving the process of care is needed in
parallel to research to improve the tools and services to optimize psychological
support for cancer survivors. Additionally, a variety of barriers to access psychosocial service exist, including the availability of providers, health-care coverage for
services, as well as patient reluctance to discuss these issues. In the USA, even
among patients who are insured, coverage of mental health services may be at
lower reimbursement levels or included in behavioral health contracts, separate
from medical coverage, posing additional barriers to access [70].
Cancer survivors have more functional limitations due to their health than age-,
gender-, and educational-attainment matched controls, with 18% unable to work
due to health problems (vs 10% for controls), 27% limited in the amount or kind
of work that they can do because of health problems (vs 18%), 5% needing help
in activities of daily living (vs 3%), and 11% needing help in independent activities
of daily living (vs 7%) [34]. A high proportion of cancer survivors have limitations
in lower-body function with 56% reporting difficulty in performing at least one of
the following activities compared with only 27% of controls: walking one-quarter
of a mile; walking up and down ten steps; standing for 2 h; stooping, crouching
or kneeling; and lifting 10 lb [35]. There are opportunities to provide the type of
care needed to mitigate the impact of these functional limitations to enhance
overall health.
2
What Is Quality Health Care for Cancer Survivors?
41
Coordination Between Specialists and Primary Care Providers
Although data are limited, anecdotal reports and several small studies suggest significant problems in communication between cancer specialists and primary care providers providing ongoing care [29, 71, 72]. A recent study of 300 breast cancer survivors
followed at an outpatient clinic of a university hospital found that only 28% thought
that their oncologists and primary care providers communicated well [72].
While a majority of cancer survivors continue to follow-up with their oncologist
for many years, the proportion of patients receiving their follow-up care solely from
primary care physicians increases over time [73, 74]. Despite having to assume
primary responsibility for survivorship care for a large proportion of cancer survivors, primary care physicians report uncertainty in their role in caring for survivors
as well as lack of knowledge regarding late effects of cancer and its treatment [75,
76]. In a recent survey of primary care physicians, half of them reported feeling
unprepared to evaluate and manage late effects of cancer treatment [7].
In 2005, in its seminal report, From Cancer Patient to Cancer Survivor: Lost in
Transition, the IOM recommended that patients completing primary cancer treatment “be provided with a comprehensive summary of their treatment together with
a survivorship follow-up care plan written by the treating health care provider(s).”
Although ASCO (available at http://www.asco.org) has developed templates and the
Journey Forward, a collaborative effort of the UCLA Cancer Survivorship Center,
NCCS, WellPoint, Inc, and Genentech (http://www.JourneyForward.org), has created tools for developing customized survivorship care plans, few oncologists have
yet to make the survivorship care plans part of their routine practice. Among
patients treated at oncology practices participating in ASCO’s Quality Oncology
Practice Initiative (QOPI), in chart abstractions only 27% had received a treatment
summary and had it communicated to the clinician providing continuing care within
3 months of completing chemotherapy in 2010. This is despite of it being a QOPI
quality indicator since 2008. Given the importance placed upon this kind of communication by primary care physicians caring for survivors, it will be critical to
develop strategies to overcome the barriers that are inhibiting the acceptance of
treatment summaries and survivorship plans by oncologists. Expectations for survivorship care differ between patients and their physicians. A lack of clarity surrounding their respective roles may contribute to suboptimal levels of care [34].
Opportunities for Improvement
While available information on the quality of the process of care for cancer survivors must be considered very preliminary, it underscores the need to shift the focus
of survivorship care from surveillance of disease recurrence, especially distant
recurrence, to the other areas of survivorship care identified by the IOM including
prevention of recurrence and new cancers; intervention for consequences of cancer
and its treatment, including functional impairment, symptom burden, psychological
distress; and coordination among specialists of several disciplines and primary care
42
J. Malin et al.
providers. While the quality of care for surveillance for second cancers appears very
good (although variation and potential disparities persist), there is substantial overuse of imaging and other tests for surveillance of distant recurrence that have not
been shown to improve outcomes and may contribute to the risk of secondary
malignancies. Gaps between existing care and ideal care are substantial for survivorship care, highlighting the urgent need of validated quality indicators both to
monitor the quality of care and guide quality improvement interventions. Additionally,
new models of care need to be explored and systematically studied as ways to
deliver higher quality survivorship care more efficiently. Survivorship clinics run by
nurse practitioners or physicians assistants and the Patient-Centered Medical Home
are two different approaches discussed further in Chaps. 10 and 11.
Identifying Barriers to Optimal Care
There are several reasons why survivorship care may be inadequate. Firstly, there
are insufficient means for identifying and addressing issues that are crucial for
cancer survivors. Follow-up appointments, often occurring in busy clinics, are often
too brief to adequately address the broad range of survivorship issues [62]. There
is an urgent need for alternative models of posttreatment care [14, 29, 77].
Clinicians lack comprehensive assessment tools that could be administered in such
an environment.
Secondly, responsibilities for follow-up are not clearly delineated between
oncologists and primary care providers. Without an established system that includes
accountability for each component of care, patients’ needs are unmet, and there is
a risk they will be lost to follow-up [4]. Even when these roles are delineated, primary care providers may lack training in survivorship issues and may not be able
to rely on communication and advice from specialists [4].
Thirdly, although the ASCO is developing guidelines [78], there is currently
insufficient evidence about the optimal frequency and content of follow-up
appointments. Existing guidelines generally focus on detecting recurrence and
second cancers and are not always easy for clinicians to access. Furthermore, evidence is lacking for self-care strategies that might improve management of treatment side effects [27]. To date, interventions have focused on limited health
promotional strategies, particularly exercise programs and the reduction of physical
side effects [24, 78]. More evidence-based support for psychosocial treatments
would greatly improve their promotion and uptake. The IOM report recommended
developing strategies to improve both physical and psychosocial outcomes [4].
Recommended Strategies to Promote Quality Survivorship Care
Much work is needed to improve survivorship care. Several priority areas and strategies have been identified to implement the above principles. Although discussed
in greater detail elsewhere in this text, a few key points are described below.
2
What Is Quality Health Care for Cancer Survivors?
43
Clinical Guidelines for Follow-up
There is a clear need for long-term continuous follow-up for cancer survivors. The
IOM report revealed limited progress had been made to develop evidence-based
guidance for providers of survivorship care. The IOM report recommended the
development of “evidence-based clinical practice guidelines, assessment tools and
screening instruments to help identify and manage late effects of cancer and its
treatment [4].” Guidelines should cover ongoing, repeat assessments and assist
clinicians to manage the complex range of survivor issues; this will ensure that
health changes related or unrelated to cancer can be detected when treatment or
intervention is most likely to be effective [25].
Screening and Management of Psychosocial Issues
All cancer survivors require screening for distress and unmet needs. Mechanisms
are also required that match these needs to interventions and other treatments.
Psychosocial outcomes and efficient use of health resources may be enhanced by
interventions tailored to the level of distress experienced [79]. Those involved in
survivorship care should be encouraged to broaden discussions with survivors to
include work, finances, and other social difficulties, and to develop appropriate
referral pathways.
Education and Training
Survivorship issues should be part of the training of all health professionals, and be
included in skills development for the current workforce. The IOM report recommended: “The National Cancer Institute, professional associations, and voluntary
organizations should expand and coordinate their efforts to provide educational opportunities to health care providers to equip them to address the health care and quality
of life issues facing cancer survivors [4].” Improved awareness of the medical and
psychosocial difficulties that can occur after cancer treatment will prompt appropriate
assessment and intervention. This, combined with a system of increased accountability for follow-up, may give clinicians greater confidence to identify and manage survivor issues directly, rather than allowing patients to be lost in a system of referrals.
Survivorship Care Plans
Communication between health-care professionals is a serious concern in survivorship care. The IOM report recommended that all patients completing primary treatment be given a comprehensive care summary and follow-up plan. This should be
44
J. Malin et al.
written by those who coordinated oncology treatment [4]. The summary should
include all diagnosis and treatment information, plus details about any toxicities
and complications experienced [12]. The care plan should recommend the frequency and duration of follow-up and a schedule for appointments, particularly if
the survivor was being treated according to a shared care model. It should also
provide strategies for dealing with current consequences of cancer and its treatments, health promotion strategies, and a list of support services.
A survivorship care plan is meant for the cancer survivor as well as their healthcare providers. Structured care plans potentially will greatly improve communication between specialists and primary care providers; in the absence of such plans,
health-care providers often rely on patient recall and understanding. There is widespread support for tailored care plans from survivors, nurses, and physicians,
although more investigation is needed to determine the best ways to prepare and
implement the plans [17, 80]. Ideally, care plans should be “living” documents that
reflect current and projected circumstances.
Exploration and Assessment of Alternate Models of Care
It is critical that various models of follow-up be explored and rigorously evaluated.
These models may include shared care models (specialist/primary care provider),
specialist survivorship clinics (including long-term follow-up clinics) and nurse-led
clinics [14, 29, 77]. Follow-up need not be face-to-face, but may be conducted by
telephone or using the Internet. Self-management strategies should also be developed. These models should be studied to determine feasibility, acceptability, and
effectiveness (including cost-effectiveness). Ideally, models should be broadly
applicable to ensure that the greatest number of survivors is included. The IOM
report has recommended that “The Centers for Medicare and Medicaid Services,
National Cancer Institute, Agency for Healthcare Research and Quality, the
Department of Veterans Affairs, and other qualified organizations should support
demonstration programs to test models of coordinated, interdisciplinary survivorship care in diverse communities and across systems of care [4].”
Conclusion
There is growing recognition of the need to improve the structure and process of care
in order to optimize the outcomes of the expanding numbers of cancer survivors.
Since much of the care of cancer survivors has heretofore focused on surveillance
for recurrence, the development of evidence-based strategies for prevention, consequences of cancer treatment, and coordination of care has lagged, limiting the development of quality indicators in these areas. However, even as research is being
conducted to develop evidence-based approaches to improve outcomes for cancer
2
What Is Quality Health Care for Cancer Survivors?
45
Table 2.4 Priority areas to improve quality survivorship care that need immediate attention
Evidence-based strategies for detection and management of late-effects of cancer therapy
Evidence-based guidelines for comprehensive survivorship care across all cancer types
Evidence-based quality indicators for comprehensive survivorship care across all cancer types
Development of a comprehensive screening tool to tailor survivorship care to individual patient
needs
Systematic review to identify best practices for delivering high quality survivorship care
Assessment of impact of imaging practices for surveillance on rates of second malignancies
Comparative effectiveness research to evaluate models for delivering survivorship care
Development of mechanisms to respond to identified gaps in high quality survivorship care
Development of quality improvement tools for survivorship care
Evaluation of coverage policies that may limit access to critical components of survivorship care
(i.e. psychosocial services)
survivors, we must determine what processes and structures of care will produce the
highest quality outcomes given current scientific knowledge. Key priority areas to
improve quality survivorship care that need immediate attention include (Table 2.4):
• Evidence-based strategies for detection and management of late-effects of
cancer therapy
• Evidence-based guidelines for comprehensive survivorship care across all
cancer types
• Evidence-based quality indicators for comprehensive survivorship care across
all cancer types
• Development of a comprehensive screening tool to tailor survivorship care to
individual patient needs
• Systematic review to identify best practices for delivering high-quality survivorship care
• Assessment of impact of imaging practices for surveillance on rates of second
malignancies
• Comparative effectiveness research to evaluate models for delivering survivorship care
• Development of mechanisms to respond to identified gaps in high-quality survivorship care
• Development of quality improvement tools for survivorship care
• Evaluation of coverage policies that may limit access to critical components of
survivorship care (i.e., psychosocial services).
References
1. Twombly R. What’s in a name: who is a cancer survivor? J Natl Cancer Inst.
2004;96(19):1414–5.
2. Jefford M. Improving outcomes for cancer survivors in Australia. Cancer Forum.
2009;33(3):159–63.
46
J. Malin et al.
3. National Coalition for Cancer Survivorship (NCCS). Official website of the National
Coalition for Cancer Survivorship. [cited 2010 July 31]; Available from: http://www.
canceradvocacy.org/about/org/.
4. Hewitt ME, Greenfield S, Stovall E, editors. From cancer patient to cancer survivor: lost in
transition. Washington, DC: The National Academies Press; 2006.
5. Boyes A, Hodgkinson K, Aldridge T, Turner J. Issues for cancer survivors in Australia.
Cancer Forum. 2009;33(3):164–7.
6. Jefford M, Karahalios E, Pollard A, Baravelli C, Carey M, Franklin J, et al. Survivorship
issues following treatment completion–results from focus groups with Australian cancer survivors and health professionals. J Cancer Surviv. 2008;2(1):20–32.
7. Hodgkinson K, Butow P, Hobbs KM, Wain G. After cancer: the unmet supportive care needs
of survivors and their partners. J Psychosoc Oncol. 2007;25(4):89–104.
8. Sanson-Fisher R, Girgis A, Boyes A, Bonevski B, Burton L, Cook P. The unmet supportive
care needs of patients with cancer. Supportive Care Review Group. Cancer.
2000;88(1):226–37.
9. Foster C, Wright D, Hill H, Hopkinson J, Roffe L. Psychosocial implications of living 5 years
or more following a cancer diagnosis: a systematic review of the research evidence. Eur J
Cancer Care (England). 2009;18(3):223–47.
10. Gotay CC, Muraoka MY. Quality of life in long-term survivors of adult-onset cancers. J Natl
Cancer Inst. 1998;90(9):656–67.
11. Foley KL, Farmer DF, Petronis VM, Smith RG, McGraw S, Smith K, et al. A qualitative
exploration of the cancer experience among long-term survivors: comparisons by cancer type,
ethnicity, gender, and age. Psychooncology. 2006;15(3):248–58.
12. Ganz PA. Monitoring the physical health of cancer survivors: a survivorship-focused medical
history. J Clin Oncol. 2006;24(32):5105–11.
13. Rowland JH, Hewitt M, Ganz PA. Cancer survivorship: a new challenge in delivering quality
cancer care. J Clin Oncol. 2006;24(32):5101–4.
14. Oeffinger KC, McCabe MS. Models for delivering survivorship care. J Clin Oncol.
2006;24(32):5117–24.
15. Institute of Medicine, Adler NE, Page AEK, editors. Cancer care for the whole patient: meeting psychosocial health needs. Washington, DC: The National Academies Press; 2008.
16. National Breast Cancer Centre and National Cancer Control Initiative. Clinical practice guidelines for the psychosocial care of adults with cancer. Camperdown, NSW, Australia: National
Breast Cancer Centre; 2003.
17. Hewitt ME, Bamundo A, Day R, Harvey C. Perspectives on post-treatment cancer care: qualitative research with survivors, nurses, and physicians. J Clin Oncol. 2007;25(16):2270–3.
18. Wolff SN. The burden of cancer survivorship. A pandemic of treatment success. In: Feuerstein
M, editor. Handbook of cancer survivorship. New York: Springer; 2007.
19. Pigott C, Pollard A, Thomson K, Aranda S. Unmet needs in cancer patients: development of
a supportive needs screening tool (SNST). Support Care Cancer. 2009;17(1):33–45.
20. Clark EJ, Stovall EL, Leigh S, Siu AL, Austin DK, Rowland JH. Imperatives for quality cancer care: access, advocacy, action, and accountability care: access advocacy, action and
accountability. Silver Spring: National Coalition for Cancer Survivorship; 1996.
21. Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century.
Washington, DC: The National Academies Press; 2001.
22. World Health Organization. Preamble to the Constitution of the World Health Organization as
adopted by the International Health Conference, New York, 19–22 June, 1946; signed on 22
July 1946 by the representatives of 61 States (Official Records of the World Health
Organization, no. 2, p. 100) and entered into force on 7 April 1948.
23. Pollard A, Eakin E, Vardy J, Hawkes A. Health behaviour interventions for cancer survivors: an
overview of the evidence and contemporary Australian trials. Cancer Forum. 2009;33(3):182–6.
24. Stull VB, Snyder DC, Demark-Wahnefried W. Lifestyle interventions in cancer survivors:
designing programs that meet the needs of this vulnerable and growing population. J Nutr.
2007;137(1 Suppl):243S–8.
2
What Is Quality Health Care for Cancer Survivors?
47
25. Earle CC. Surveillance after primary therapy. In: Ganz PA, editor. Cancer survivorship: today
and tomorrow. New York: Springer; 2007. p. 43–53.
26. Ganz PA. Quality of care and cancer survivorship: the challenge of implementing the institute
of medicine recommendations. J Oncol Pract. 2009;5:101–5.
27. Lotfi-Jam K, Carey M, Jefford M, Schofield P, Charleson C, Aranda S. Nonpharmacologic
strategies for managing common chemotherapy adverse effects: a systematic review. J Clin
Oncol. 2008;26(34):5618–29.
28. Newell SA, Sanson-Fisher RW, Savolainen NJ. Systematic review of psychological therapies
for cancer patients: overview and recommendations for future research. J Natl Cancer Inst.
2002;94(8):558–84.
29. Brennan M, Jefford M. General practitioner-based models of post-treatment follow up. Cancer
Forum. 2009;33(3):179–82.
30. Lotfi-Jam K, Schofield P, Jefford M. What constitutes ideal survivorship care? Cancer Forum.
2009;33(3):171–4.
31. Stein KD, Syrjala KL, Andrykowski MA. Physical and psychological long-term and late
effects of cancer. Cancer. 2008;112(11 Suppl):2577–92.
32. Arora NK. Importance of patient-centered care in enhancing patient well-being: a cancer
survivor’s perspective. Qual Life Res. 2009;18(1):1–4.
33. Lohr KN, Schroeder SA. A strategy for quality assurance in Medicare. N Engl J Med.
1990;322(10):707–12.
34. Yabroff KR, Lawrence WF, Clauser S, Davis WW, Brown ML. Burden of illness in cancer
survivors: findings from a population-based national sample. J Natl Cancer Inst.
2004;96(17):1322–30.
35. Schootman M, Aft R, Jeffe DB. An evaluation of lower-body functional limitations among
long-term survivors of 11 different types of cancers. Cancer. 2009;115(22):5329–38.
36. Donabedian A. The quality of medical care: a concept in search of a definition. J Fam Pract.
1979;9(2):277–84.
37. National Cancer Policy Board, Institute of Medicine and Commission on Life Sciences,
National Research Council. In: Hewitt M, Simone JV, editors. Ensuring quality cancer care.
Washington, DC: The National Academies Press; 1999.
38. Jacobson JO, Neuss MN, McNiff KK, Kadlubek P, Thacker 2nd LR, Song F, et al.
Improvement in oncology practice performance through voluntary participation in the Quality
Oncology Practice Initiative. J Clin Oncol. 2008;26(11):1893–8.
39. Desch CE, McNiff KK, Schneider EC, Schrag D, McClure J, Lepisto E, et al. American
Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures.
J Clin Oncol. 2008;26(21):3631–7.
40. National Quality Forum: Quality of Cancer Care Performance Measures [Internet]. [cited
2008 Nov 20]. Available from: http://www.qualityforum.org/Projects/c-d/Cancer_Care_
Phase_II/Cancer_Care_Phase_II.aspx.
41. Spencer BA, Steinberg M, Malin J, Adams J, Litwin MS. Quality-of-care indicators for earlystage prostate cancer. J Clin Oncol. 2003;21(10):1928–36.
42. Gagliardi AR, Fleshner N, Langer B, Stern H, Brown AD. Development of prostate cancer
quality indicators: a modified Delphi approach. Can J Urol. 2005;12(5):2808–15.
43. Malin JL, Asch SM, Kerr EA, McGlynn EA. Evaluating the quality of cancer care: development of cancer quality indicators for a global quality assessment tool. Cancer.
2000;88(3):701–7.
44. Rubins J, Unger M, Colice GL. Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition).
Chest. 2007;132(3 Suppl):355S–67.
45. Smoking Cessation and Continued Risk in Cancer Patients (PDQ®) [Internet]. National
Cancer Institute; [updated 2010 April 14; cited 2010 Mar 23]. Available from: http://www.
cancer.gov/cancertopics/pdq/supportivecare/smokingcessation/HealthProfessional/allpages.
46. American Society of Clinical Oncology. Tobacco Cessation and Quality Cancer Care. J Oncol
Pract. 2009;5:2–5.
48
J. Malin et al.
47. Malin JL, Schneider EC, Epstein AM, Adams J, Emanuel EJ, Kahn KL. Results of the
National Initiative for Cancer Care Quality: how can we improve the quality of cancer care in
the United States? J Clin Oncol. 2006;24(4):626–34.
48. Owusu C, Buist DS, Field TS, Lash TL, Thwin SS, Geiger AM, et al. Predictors of tamoxifen
discontinuation among older women with estrogen receptor-positive breast cancer. J Clin
Oncol. 2008;26(4):549–55.
49. Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA. Adherence to tamoxifen over the fiveyear course. Breast Cancer Res Treat. 2006;99(2):215–20.
50. Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM. Patient centered experiences in
breast cancer: predicting long-term adherence to tamoxifen use. Med Care.
2007;45(5):431–9.
51. Snyder CF, Frick KD, Kantsiper ME, Peairs KS, Herbert RJ, Blackford AL, et al. Prevention,
screening, and surveillance care for breast cancer survivors compared with controls: changes
from 1998 to 2002. J Clin Oncol. 2009;27(7):1054–61.
52. Cooper GS, Kou TD, Reynolds Jr HL. Receipt of guideline-recommended follow-up in older
colorectal cancer survivors: a population-based analysis. Cancer. 2008;113(8):2029–37.
53. Barzilai DA, Cooper KD, Neuhauser D, Rimm AA, Cooper GS. Geographic and patient
variation in receipt of surveillance procedures after local excision of cutaneous melanoma.
J Investig Dermatol. 2004;122(2):246–55.
54. Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic
follow-up after treatment of primary breast cancer. A randomized trial. National Research
Council Project on Breast Cancer follow-up. JAMA. 1994;271(20):1593–7.
55. Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O’Fallon JR. Utility of follow-up
tests for detecting recurrent disease in patients with malignant melanomas. JAMA.
1995;274(21):1703–5.
56. A Data Book: Health Care Spending and the Medicare Program [Internet]. Washington DC:
Medicare Payment Advisory Commission [cited 23 Mar 2010]. 2009. http://www.medpac.
gov/documents/Jun09DataBookEntireReport.pdf.
57. Miles KA. Cancer imaging: is it cost-effective? Cancer Imaging. 2004;4(2):97–103.
58. Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hunt E, et al. Relationship between
cancer type and impact of PET and PET/CT on intended management: findings of the national
oncologic PET registry. J Nucl Med. 2008;49(12):1928–35.
59. Brix G, Nissen-Meyer S, Lechel U, Nissen-Meyer J, Griebel J, Nekolla EA, et al. Radiation
exposures of cancer patients from medical X-rays: how relevant are they for individual
patients and population exposure? Eur J Radiol. 2009;72(2):342–7.
60. Berrington de Gonzalez A, Mahesh M, Kim KP, Bhargavan M, Lewis R, Mettler F, et al.
Projected cancer risks from computed tomographic scans performed in the United States in
2007. Arch Intern Med. 2009;169(22):2071–7.
61. Smith-Bindman R, Lipson J, Marcus R, Kim KP, Mahesh M, Gould R, et al. Radiation dose
associated with common computed tomography examinations and the associated lifetime
attributable risk of cancer. Arch Intern Med. 2009;169(22):2078–86.
62. Beaver K, Luker KA. Follow-up in breast cancer clinics: reassuring for patients rather than
detecting recurrence. Psychooncology. 2005;14(2):94–101.
63. Greenberg CC, Schneider EC, Lipsitz SR, Ko CY, Malin JL, Epstein AM, et al. Do variations
in provider discussions explain socioeconomic disparities in postmastectomy breast reconstruction? J Am Coll Surg. 2008;206(4):605–15.
64. Chen JY, Malin J, Ganz PA, Ko C, Tisnado D, Tao ML, et al. Variation in physician-patient
discussion of breast reconstruction. J Gen Intern Med. 2009;24(1):99–104.
65. Schneider EC, Malin JL, Kahn KL, Ko CY, Adams J, Epstein AM. Surviving colorectal cancer: patient-reported symptoms 4 years after diagnosis. Cancer. 2007;110(9):2075–82.
66. Chand M, Nash GF, Talbot RW. Timely closure of loop ileostomy following anterior resection
for rectal cancer. Eur J Cancer Care (England). 2008;17(6):611–5.
67. Armes J, Crowe M, Colbourne L, Morgan H, Murrells T, Oakley C, et al. Patients’ supportive
care needs beyond the end of cancer treatment: a prospective, longitudinal survey. J Clin
Oncol. 2009;27(36):6172–9.
2
What Is Quality Health Care for Cancer Survivors?
49
68. Vodermaier A, Linden W, Siu C. Screening for emotional distress in cancer patients: a systematic review of assessment instruments. J Natl Cancer Inst. 2009;101(21):1464–88.
69. Jacobsen PB. Clinical practice guidelines for the psychosocial care of cancer survivors: current status and future prospects. Cancer. 2009;115(18 Suppl):4419–29.
70. Hewitt M, Herdman R, Holland J, editors. National Research Council. Meeting psychosocial
needs of women with breast cancer. Washington, DC: National Academy Press, 2004. http://
www.nap.edu/catalog/10909.html. Accessed 2010 Aug 11.
71. Cheung WY, Neville BA, Cameron DB, Cook EF, Earle CC. Comparisons of patient and
physician expectations for cancer survivorship care. J Clin Oncol. 2009;27(15):2489–95.
72. Mao JJ, Bowman MA, Stricker CT, DeMichele A, Jacobs L, Chan D, et al. Delivery of survivorship care by primary care physicians: the perspective of breast cancer patients. J Clin
Oncol. 2009;27(6):933–8.
73. Haggstrom DA, Arora NK, Helft P, Clayman ML, Oakley-Girvan I. Follow-up care delivery
among colorectal cancer survivors most often seen by primary and subspecialty care physicians. J Gen Intern Med. 2009;24 Suppl 2:S472–9.
74. Snyder CF, Earle CC, Herbert RJ, Neville BA, Blackford AL, Frick KD. Preventive care for
colorectal cancer survivors: a 5-year longitudinal study. J Clin Oncol. 2008;26(7):1073–9.
75. Bober SL, Recklitis CJ, Campbell EG, Park ER, Kutner JS, Najita JS, et al. Caring for cancer
survivors: a survey of primary care physicians. Cancer. 2009;115(18 Suppl):4409–18.
76. Lynch T, Goldberg W, Carey J, Varga J. A preliminary examination of primary care providers’
self-reported ability and comfort with coordinating care for cancer survivors. American
Psychosocial Oncology Society Annual Conference in New Orleans, Louisiana; February 19,
2010.
77. Gates P, Krishnasamy M. Nurse-led survivorship care. Cancer Forum. 2009;33(3):175–8.
78. American Society of Clinical Oncology 2009. Clinical Practice Guidelines. 2009. http://www.
asco.org/ASCOv2/Practice+%26+Guidelines/Guidelines/Clinical+Practice+Guidelines.
Accessed 2009 Sept 17.
79. Hutchison SD, Steginga SK, Dunn J. The tiered model of psychosocial intervention in cancer:
a community based approach. Psychooncology. 2006;15(6):541–6.
80. Baravelli C, Krishnasamy M, Pezaro C, Schofield P, Lotfi-Jam K, Rogers M, et al. The views
of bowel cancer survivors and health care professionals regarding survivorship care plans and
post treatment follow up. J Cancer Surviv. 2009;3(2):99–108.
http://www.springer.com/978-1-4419-1347-0